Psilocybin has demonstrated promising clinical outcomes for nicotine and alcohol use disorders, yet its potential clinical utility in the treatment of opioid use disorder (OUD) remains unreported in modern literature. This technical report presents methodological considerations and preliminary data from a safety-feasibility trial examining the interaction between psilocybin and buprenorphine in two adults diagnosed with OUD.
Procedures:
Two adults meeting eligibility criteria for long-term stabilization of buprenorphine/naloxone (≥6 months) enrolled and underwent two psilocybin dosing sessions in a supportive setting. Preliminary data pertaining to the safety, clinical outcomes, and subjective effects of psilocybin were collected.
Main Findings:
Two participants received psilocybin and completed all study visits. Feasibility considerations were identified, including limitations in provider-based recruitment strategies, participant accessibility, flexibility of the study schedule, and initial eligibility criteria. There were no serious adverse events or significant baseline changes on measures of opioid craving or withdrawal, and the subjective effects associated with psilocybin were consistent with previous studies.
Principal Conclusions:
Coadministration of psilocybin and buprenorphine was safely tolerated and did not demonstrate contraindicating effects vis-à-vis effectiveness of buprenorphine or the subjective effects of psilocybin. Challenges in feasibility led to modifications in the sample population and eligibility criteria and strategies to improve accessibility, minimize burden, and enhance overall generalizability.
clinicaltrials.gov ID: NCT05242029.
Get full access to this article
View all access options for this article.
References
1.
U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (2023). National Survey on Drug Use and Health 2021 (NSDUH-2021-DS0001). Available from: https://datafiles.samhsa.gov/
2.
LarochelleMR, BernsonD, LandT, et al.Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A Cohort Study. Ann Intern Med, 2018; 169(3):137–145; doi: 10.7326/M17-3107
3.
MattickRP, BreenC, KimberJ, et al.Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev, 2009;(3):CD002209; doi: 10.1002/14651858.CD002209.pub2
4.
MattickRP, BreenC, KimberJ, et al.Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev, 2014;(2):CD002207; doi: 10.1002/14651858.CD002207.pub4
5.
SofuogluM, DeVitoEE, CarrollKM. Pharmacological and behavioral treatment of opioid use disorder. PRCP, 2019; 1(1):4–15; doi: 10.1176/appi.prcp.20180006
6.
HodgeAT, Sukpraprut-BraatenS, NarleskyM, et al.The use of psilocybin in the treatment of psychiatric disorders with attention to relative safety profile: A systematic review. J Psychoactive Drugs, 2022; 1–11; doi: 10.1080/02791072.2022.2044096
7.
HortonDM, MorrisonB, SchmidtJ. Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy. Am J Psychother, 2021; 74(4):140–149; doi: 10.1176/appi.psychotherapy.20200055
8.
Anonymous. FDA Grants Psilocybin Second Breakthrough Therapy Designation. n.d. Available from: https://www.medscape.com/viewarticle/921789 [Last accessed: January27, 2023].
9.
BogenschutzMP, ForcehimesAA, PommyJA, et al.Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol, 2015; 29(3):289–299; doi: 10.1177/0269881114565144
10.
BogenschutzMP, RossS, BhattS, et al.Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 2022; 79(10):953–962; doi: 10.1001/jamapsychiatry.2022.2096
11.
JohnsonMW, Garcia-RomeuA, CosimanoMP, et al.Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol, 2014; 28(11):983–992; doi: 10.1177/0269881114548296
12.
JohnsonMW, Garcia-RomeuA, GriffithsRR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse, 2017; 43(1):55–60; doi: 10.3109/00952990.2016.1170135
13.
PisanoVD, PutnamNP, KramerHM, et al.The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol, 2017; 31(5):606–613; doi: 10.1177/0269881117691453
14.
JonesG, RicardJA, LipsonJ, et al.Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Sci Rep, 2022; 12(1):4099; doi: 10.1038/s41598-022-08085-4
15.
Garcia-RomeuA, DavisAK, ErowidE, et al.Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Front Psychiatry, 2020; 10:955.
16.
SavageC, McCabeOL. Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. Arch Gen Psychiatry, 1973; 28(6):808–814; doi: 10.1001/archpsyc.1973.01750360040005
17.
DossMK, PovažanM, RosenbergMD, et al.Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry, 2021; 11(1):574; doi: 10.1038/s41398-021-01706-y
18.
OsajiJ, OjimbaC, AhmedS. The use of acceptance and commitment therapy in substance use disorders: A review of literature. J Clin Med Res, 2020; 12(10):629–633; doi: 10.14740/jocmr4311
19.
EleftheriouME, ThomasE. Examining the potential synergistic effects between mindfulness training and psychedelic-assisted therapy. Front Psychiatry, 2021; 12:707057; doi: 10.3389/fpsyt.2021.707057
20.
HeuschkelK, KuypersKPC. Depression, mindfulness, and psilocybin: Possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review. Front Psychiatry, 2020; 11:224; doi: 10.3389/fpsyt.2020.00224
21.
ParisiA, LandichoHL, HudakJ, et al.Emotional distress and pain catastrophizing predict cue-elicited opioid craving among chronic pain patients on long-term opioid therapy. Drug Alcohol Depend, 2022; 233:109361; doi: 10.1016/j.drugalcdep.2022.109361
22.
TeixeiraPJ, JohnsonMW, TimmermannC, et al.Psychedelics and health behaviour change. J Psychopharmacol, 2022; 36(1):12–19; doi: 10.1177/02698811211008554
23.
HendricksPS.Awe: A putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int Rev Psychiatry, 2018; 30(4):331–342; doi: 10.1080/09540261.2018.1474185
24.
Garcia-RomeuA, GriffithsRR, JohnsonMW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev, 2014; 7(3):157–164.
25.
KellyJF, EddieD. The role of spirituality and religiousness in aiding recovery from alcohol and other drug problems: An invistigation in a national U.S. sample. Psycholog Relig Spiritual, 2020; 12(1):116–123; doi: 10.1037/rel0000295
26.
KraehenmannR, PrellerKH, ScheideggerM, et al.Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry, 2015; 78(8):572–581; doi: 10.1016/j.biopsych.2014.04.010
27.
WattsR, DayC, KrzanowskiJ, et al.Patients' accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J Humanist Psychol, 2017; 57:520–564; doi: 10.1177/0022167817709585
28.
ChristieNC.The role of social isolation in opioid addiction. Soc Cogn Affect Neurosci, 2021; 16(7):645–656; doi: 10.1093/scan/nsab029
29.
DingleGA, NevesDdC, AlhadadSSJ, et al.Individual and interpersonal emotion regulation among adults with substance use disorders and matched controls. Br J Clin Psychol, 2018; 57(2):186–202; doi: 10.1111/bjc.12168
30.
BakerTB, PiperME, McCarthyDE, et al.Addiction motivation reformulated: An affective processing model of negative reinforcement. Psychol Rev, 2004; 111(1):33–51; doi: 10.1037/0033-295X.111.1.33
31.
ShaoL-X, LiaoC, GreggI, et al.Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 2021; 109(16):2535–2544.e4; doi: 10.1016/j.neuron.2021.06.008
32.
SkosnikPD, SloshowerJ, Safi-AghdamH, et al.Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. J Psychopharmacol, 2023; 2698811231179800; doi: 10.1177/02698811231179800
33.
KočárováR, HoráčekJ, Carhart-HarrisR. Does psychedelic therapy have a transdiagnostic action and prophylactic potential?. Front Psychiatry, 2021; 12:661233; doi: 10.3389/fpsyt.2021.661233
34.
LyC, GrebAC, CameronLP, et al.Psychedelics promote structural and functional neural plasticity. Cell Rep, 2018; 23(11):3170–3182; doi: 10.1016/j.celrep.2018.05.022
35.
Carhart-HarrisRL, FristonKJ. REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacol Rev, 2019; 71(3):316–344; doi: 10.1124/pr.118.017160
ParisiA, RobertsRL, HanleyAW, et al.Mindfulness-oriented recovery enhancement for addictive behavior, psychiatric distress, and chronic pain: A multilevel meta-analysis of randomized controlled trials. Mindfulness (N Y), 2022; 13(10):2396–2412; doi: 10.1007/s12671-022-01964-x
38.
HaiAH, FranklinC, ParkS, et al.The efficacy of spiritual/religious interventions for substance use problems: A systematic review and meta-analysis of randomized controlled trials. Drug Alcohol Depend, 2019; 202:134–148; doi: 10.1016/j.drugalcdep.2019.04.045
39.
ShoreyRC, GawrysiakMJ, ElmquistJ, et al.Experiential avoidance, distress tolerance, and substance use cravings among adults in residential treatment for substance use disorders. J Addict Dis, 2017; 36(3):151–157; doi: 10.1080/10550887.2017.1302661
40.
KellyJF, GreeneMC. Where there's a will there's a way: A longitudinal investigation of the interplay between recovery motivation and self-efficacy in predicting treatment outcome. Psychol Addict Behav, 2014; 28(3):928–934; doi: 10.1037/a0034727
41.
WyseJJ, MorascoBJ, DoughertyJ, et al.Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence. Drug Alcohol Depend, 2021; 228:108923; doi: 10.1016/j.drugalcdep.2021.108923
42.
JohnsonM, RichardsW, GriffithsR. Human hallucinogen research: Guidelines for safety. J Psychopharmacol, 2008; 22(6):603–620; doi: 10.1177/0269881108093587
43.
HartogsohnI.Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J Psychopharmacol, 2016; 30(12):1259–1267; doi: 10.1177/0269881116677852
44.
TimmermannC, WattsR, DupuisD. Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations. Transcult Psychiatry, 2022; 59(5):691–704; doi: 10.1177/13634615221082796
45.
BrownRT, NicholasCR, CozziNV, et al.Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet, 2017; 56(12):1543–1554; doi: 10.1007/s40262-017-0540-6
46.
NicholasCR, HenriquezKM, GassmanMC, et al.High dose psilocybin is associated with positive subjective effects in healthy volunteers. J Psychopharmacol, 2018; 32(7):770–778; doi: 10.1177/0269881118780713
47.
MarekGJ.Behavioral evidence for mu-opioid and 5-HT2A receptor interactions. Eur J Pharmacol, 2003; 474(1):77–83; doi: 10.1016/s0014-2999(03)01971-x
48.
SheehanDV, LecrubierY, SheehanKH, et al.The Mini-International Neuropsychiatric Interview (M.I.N.I): The Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10. J Clin Psychiatry, 1998.
49.
SheehanDV, LecrubierY, SheehanKH, et al.The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry, 1997; 12(5):232–241; doi: 10.1016/S0924-9338(97)83297-X
50.
LecrubierY, SheehanD, WeillerE, et al.The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and validity according to the CIDI. Eur Psychiatry, 1997; 12(5):224–231; doi: 10.1016/S0924-9338(97)83296-8
51.
FirstMB.Structured Clinical Interview for the DSM (SCID). In: The Encyclopedia of Clinical Psychology. John Wiley & Sons, Ltd;, 2015; pp. 1–6; doi: 10.1002/9781118625392.wbecp351
52.
Anonymous. (PDF) Investigator's Brochure Psilocybin Investigator's Brochure V 1.1 Usona Institute 18-Feb-18. Page 2 of 59 Psilocybin Investigator's Brochure Amendments. DOCUMENT HISTORY. n.d. Available from: https://pdfslide.net/documents/investigators-brochure-psilocybin-investigators-brochure-v-11-usona-institute.html [Last accessed: January27, 2023].
53.
JohnsonMW, SewellRA, GriffithsRR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend, 2012; 123(1–3):132–140; doi: 10.1016/j.drugalcdep.2011.10.029
McHughRK, TrinhCD, GriffinML, et al.Validation of the craving scale in a large sample of adults with substance use disorders. Addict Behav, 2021; 113:106651; doi: 10.1016/j.addbeh.2020.106651
56.
Fals-StewartW, O FarrellTJ, FreitasTT, et al.The Timeline Followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties. J Consul Clin Psychol, 2000; 68:134–144; doi: 10.1037/0022-006X.68.1.134
57.
Carhart-HarrisRL, BolstridgeM, RuckerJ, et al.Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry, 2016; 3(7):619–627; doi: 10.1016/S2215-0366(16)30065-7
58.
GriffithsRR, JohnsonMW, CarducciMA, et al.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016; 30(12):1181–1197; doi: 10.1177/0269881116675513
59.
GriffithsRR, JohnsonMW, RichardsWA, et al.Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology, 2011; 218(4):649–665; doi: 10.1007/s00213-011-2358-5
60.
SahsJA, NicasioAV, StoreyJE, et al.Developing research collaborations in an academic clinical setting: Challenges and lessons learned. Community Ment Health J, 2017; 53(6):647–660; doi: 10.1007/s10597-016-0073-8
61.
FosterJM, SawyerSM, SmithL, et al.Barriers and facilitators to patient recruitment to a cluster randomized controlled trial in primary care: Lessons for future trials. BMC Med Res Methodol, 2015; 15:18; doi: 10.1186/s12874-015-0012-3
62.
MasonVL, ShawA, WilesNJ, et al.GPs' experiences of primary care mental health research: A qualitative study of the barriers to recruitment. Fam Pract, 2007; 24(5):518–525; doi: 10.1093/fampra/cmm047
63.
BradleyM, ChaharP.Burnout of healthcare providers during COVID-19. Cleve Clin J Med, 2020. [Epub ahead of print]; doi: 10.3949/ccjm.87a.ccc051
64.
TuttleKR.Impact of the COVID-19 pandemic on clinical research. Nat Rev Nephrol, 2020; 16(10):562–564; doi: 10.1038/s41581-020-00336-9
65.
AudisioK, LiaH, RobinsonNB, et al.Impact of the COVID-19 pandemic on non-COVID-19 clinical trials. J Cardiovasc Dev Dis, 2022; 9(1):19; doi: 10.3390/jcdd9010019
66.
DillahuntTR, VeinotTC. Getting there: Barriers and facilitators to transportation access in underserved communities. ACM Trans Comput Hum Interact, 2018; 25(5):29:1–29:39; doi: 10.1145/3233985
67.
KoK, KnightG, RuckerJJ, et al.Psychedelics, mystical experience, and therapeutic efficacy: A systematic review. Front Psychiatry, 2022; 13:917199; doi: 10.3389/fpsyt.2022.917199
68.
HirschfeldT, SchmidtTT. Dose-response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol, 2021; 35(4):384–397; doi: 10.1177/0269881121992676
69.
StuderusE, KometerM, HaslerF, et al.Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol, 2011; 25(11):1434–1452; doi: 10.1177/0269881110382466
70.
HandelsmanL, CochraneKJ, AronsonMJ, et al.Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse, 1987; 13(3):293–308; doi: 10.3109/00952998709001515
71.
MahoneyJJ, WinstanleyEL, LanderLR, et al.High prevalence of co-occurring substance use in individuals with opioid use disorder. Addict Behav, 2021; 114:106752; doi: 10.1016/j.addbeh.2020.106752
72.
TormohlenKN, MojtabaiR, SeiwellA, et al.Co-occurring opioid use and depressive disorders: patient characteristics and co-occurring health conditions. J Dual Diagn, 2021; 17(4):296–303; doi: 10.1080/15504263.2021.1979349
73.
SpreenLA, DittmarEN, QuirkKC, et al.Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review. Pharmacotherapy, 2022; 42(5):411–427; doi: 10.1002/phar.2676
74.
Carhart-HarrisR, GiribaldiB, WattsR, et al.Trial of psilocybin versus escitalopram for depression. N Engl J Med, 2021; 384(15):1402–1411; doi: 10.1056/NEJMoa2032994
75.
O'DonnellKC, MennengaSE, BogenschutzMP. Psilocybin for depression: Considerations for clinical trial design. J Psychedelic Stud, 2019; 3(3):269–279; doi: 10.1556/2054.2019.026
76.
MosesonH, KumarS, JuusolaJL. Comparison of study samples recruited with virtual versus traditional recruitment methods. Contemp Clin Trials Commun, 2020; 19:100590; doi: 10.1016/j.conctc.2020.100590
77.
LaiYS, AfsethJD. A review of the impact of utilising electronic medical records for clinical research recruitment. Clin Trials, 2019; 16(2):194–203; doi: 10.1177/1740774519829709
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
